Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib works in treating patients with kidney
cancer that has spread to the brain. Sorafenib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth and by blocking blood flow to the tumor.